Cargando…
Phase II Study of Paclitaxel in Patients With Soft Tissue Sarcomas
Purpose. Patients with soft tissue sarcoma (STS) who have previously received standard chemotherapy including adriamycin (doxorubicin), ifosfamide, cyclophosphamide and DTIC (dacarbazine) have very limited therapeutic options. It is important to identify new drugs with some activity in this disease...
Autores principales: | Patel, Shreyaskumar R., Linke, Kaye A., Burgess, M. Andrew, Papadopoulos, Nicholas E., Plager, Carl, Jenkins, Jan, Benjamin, Robert |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
1997
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395357/ https://www.ncbi.nlm.nih.gov/pubmed/18521208 http://dx.doi.org/10.1080/13577149778362 |
Ejemplares similares
-
Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma
por: Nguyen, James, et al.
Publicado: (2023) -
Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020) -
Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma
por: Dickson, Mark A., et al.
Publicado: (2015) -
EORTC Group Phase II Study of Oral Etoposide for Pretreated Soft Tissue Sarcoma
por: Keizer, H. Jan, et al.
Publicado: (1997) -
Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group
por: Bafaloukos, D, et al.
Publicado: (2004)